inflammatory arthritis caused by the BNT162b2 COVID vaccination; a rash overlying a few joints (the left ankle, the right knee, and the right wrist); the rash was migratory, pruritic and papular in quality; the rash was migratory, pruritic and papular in quality; serum sickness-like reaction due to the COVID-19 vaccine; This is a literature report for the following literature source(s):   A 74-year-old male patient received BNT162b2 (BNT162B2), in Jan2021 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "obstructive sleep apnea" (unspecified if ongoing); "depression" (unspecified if ongoing); "idiopathic pulmonary fibrosis" (unspecified if ongoing); "hypertension" (unspecified if ongoing); "gout" (unspecified if ongoing); "asbestos exposure" (unspecified if ongoing); "polyarthralgia" (unspecified if ongoing); "asbestos exposure" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Nintedanib for idiopathic pulmonary fibrosis, notes: 150mg twice daily. The following information was reported: SERUM SICKNESS-LIKE REACTION (medically significant) with onset Feb2021, 10 days after the suspect product(s) administration, outcome "unknown", described as "serum sickness-like reaction due to the COVID-19 vaccine"; ARTHRITIS (medically significant), 10 days after the suspect product(s) administration, outcome "unknown", described as "inflammatory arthritis caused by the BNT162b2 COVID vaccination"; RASH (non-serious), 10 days after the suspect product(s) administration, outcome "recovered", described as "a rash overlying a few joints (the left ankle, the right knee, and the right wrist)"; RASH PAPULAR (non-serious), 10 days after the suspect product(s) administration, outcome "recovered", RASH PRURITIC (non-serious), outcome "recovered" and all described as "the rash was migratory, pruritic and papular in quality". The patient underwent the following laboratory tests and procedures: Anti-cyclic citrullinated peptide antibody: (05Mar2021) less than 1.5, notes: units: U/ml; Antinuclear antibody: (18Feb2021) 1:320 homogenous; (unspecified date) Negative; Blood albumin: (31Mar2021) 3.5 g/dl; (14Apr2021) 3.6 g/dl; Blood creatine phosphokinase: (31Mar2021) 67, notes: Units: U/L; Blood lactate dehydrogenase: (31Mar2021) 258, notes: Units: U/L; Blood uric acid: (18Feb2021) 3.6 mg/dl; (03Sep2021) 3.6 mg/dl; Complement factor C3: (05Mar2021) 123 mg/dl; Complement factor C4: (05Mar2021) 21 mg/dl; C-reactive protein: (18Feb2021) 15.4 mg/l; (05Mar2021) 27.2 mg/l; (31Mar2021) 55.9 mg/l; (14Apr2021) 10.5 mg/l; (03Jun2021) 5 mg/l; (03Sep2021) 35 mg/l; (unspecified date) trended down; Haemoglobin: (18Feb2021) 15.8 g/dl; (31Mar2021) 14.6 g/dl; (03Jun2021) 14.7 g/dl; (03Sep2021) 14.9 g/dl; Hepatitis viral test: (18Feb2021) Negative; Grind test: (18Feb2021) positive; laboratory workup: (unspecified date) revealed a significant rise in his RF, notes: and no was available at the time; physical exam: (unspecified date) revealed motor power of 5/5 in all limbs; (unspecified date) and tenderness to palpation of the right AC, notes: acromioclavicular (AC) joint with positive grind test; (18Feb2021) tenderness to palpation of the first CMC, notes: carpometacarpal (CMC) joint with a positive grind test; Platelet count: (18Feb2021) 236000, notes: units: k/cmm; (31Mar2021) 253000, notes: units: k/cmm; (03Jun2021) 208000, notes: units: k/cmm; (03Sep2021) 23900, notes: units: k/cmm; Red blood cell sedimentation rate: (18Feb2021) 6, notes: Units: mm/hr; (31Mar2021) 14, notes: Units: mm/hr; (03Jun2021) 4, notes: Units: mm/hr; (03Sep2021) 32, notes: Units: mm/hr; Rheumatoid factor: (18Feb2021) 24 IU/ml; (03Sep2021) 74 IU/ml; Serology test: (unspecified date) Negative. Therapeutic measures were taken as a result of serum sickness-like reaction, arthritis, rash, rash papular, rash pruritic.  Follow-up attempts are completed. No further information is expected.   Follow up (08Nov2022): This is a literature report for the following literature source This is a follow-up report based on the receipt of the publication; the case has been updated to include additional information identified in the publication. Updated information included: Primary reporter and literature information were updated. Lab data were updated. Added dosage regimen. Events were added.; Sender's Comments: Based on limited information in the case , a possible causal association between  the reported  events Serum sickness-like reaction , Arthritis and the suspect drug cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202201280037 Same Article/drug/event and different patient;US-PFIZER INC-PV202200097379 Same Article/drug/event and different patient;US-PFIZER INC-202201287752 Same Article/drug/event and different patient;US-PFIZER INC-202201287753 same article/ patient and different drug/event;